Amgen (NASDAQ:AMGN) will present at the 2025 J.P. Morgan Healthcare Conference at 3:00 p.m. PT on Monday, January 13, 2025.
Amgen has a strong product portfolio, pipeline developments, and robust financial health. Read why AMGN stock is a Strong Buy ...
Amgen Inc. closed $84.79 short of its 52-week high ($346.85), which the company achieved on July 25th.
The Amgen stock price suffered a harsh reversal in the fourth quarter of 2024 as its weight loss drug failed to excite. After ...
Shares of Amgen Inc. AMGN slipped 1.01% to $258.59 Monday, on what proved to be an all-around mixed trading session for the ...
Truist lowered the firm’s price target on Amgen (AMGN) to $298 from $333 and keeps a Hold rating on the shares as part of a broader research ...
Amgen’s bispecific T-cell engager (BiTE) led to an ORR of 41% in patients with extensive-stage small cell lung cancer.
Article analyzes Amgen's strong clinical progress and financials, recommending caution due to valuation and technical ...
After opening its first facility in Ohio this year, biopharmaceutical processor Amgen has purchased an additional 22 acres ...
Here's why Amgen increased its land holdings in New Albany, even though the pharma giant has plenty of room for expansion on ...
Bearish flow noted in Amgen (AMGN) with 6,559 puts trading, or 1.0x expected. Most active are Feb-25 240 puts and 1/10 weekly 260 calls, with ...
Amgen (AMGN) concluded the recent trading session at $258.59, signifying a -1.01% move from its prior day's close.